Scarica l'app Stockscreener
17.09
0.47%
-0.08
Dopo l'orario di chiusura:
17.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$17.17
Aprire:
$16.61
Volume 24 ore:
1.24M
Relative Volume:
0.77
Capitalizzazione di mercato:
$1.37B
Reddito:
$123.67M
Utile/perdita netta:
$-38.63M
Rapporto P/E:
-27.70
EPS:
-0.617
Flusso di cassa netto:
$-27.50M
1 W Prestazione:
+9.06%
1M Prestazione:
-7.62%
6M Prestazione:
+123.98%
1 anno Prestazione:
+287.53%
Intervallo 1D:
$16.61
$17.88
Intervallo di 1 settimana:
$15.29
$17.88
Portata 52W:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
17.09 | 1.37B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Quarterly Earnings: How sensitive is Monte Rosa Therapeutics Inc to inflation2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Gainers Report: What are the risks of holding Monte Rosa Therapeutics IncRisk Management & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aug Patterns: Can Monte Rosa Therapeutics Inc lead its sector in growth2026 Technicals & Weekly Momentum Picks - baoquankhu1.vn
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)? - simplywall.st
Trading Recap: Will Monte Rosa Therapeutics Inc benefit from AI trends2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement - Sahm
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Therapeutics urges new pathways for the next generation of scientists - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Aug Ideas: Can Monte Rosa Therapeutics Inc lead its sector in growthQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Can Monte Rosa Therapeutics Inc lead its sector in growthTrade Ideas & Long-Term Capital Growth Ideas - baoquankhu1.vn
Breakouts Watch: How sensitive is Monte Rosa Therapeutics Inc to inflationQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Big Picture: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialRate Hike & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Yahoo Finance
Wall Street Zen Downgrades Monte Rosa Therapeutics to 'Sell' - National Today
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Risks Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Does Monte Rosa Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim - TipRanks
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics (GLUE) reports Q4 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Monte Rosa Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Monte Rosa Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Monte Rosa Therapeutics (GLUE) 2025 Financials: Q4 Loss, Revenue MissNews and Statistics - IndexBox
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - MarketBeat
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls - marketscreener.com
Monte Rosa Therapeutics: Q4 Earnings Snapshot - Barchart
Monte Rosa Therapeutics : Corporate Presentation – March 2026 - marketscreener.com
Monte Rosa Therapeutics (NASDAQ: GLUE) touts MGD pipeline and major Novartis, Roche deals - Stock Titan
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments - TradingView
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M - marketscreener.com
Monte Rosa Therapeutics (GLUE) extends cash runway to 2029 after $345M raise - Stock Titan
Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story? - simplywall.st
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ) - Seeking Alpha
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Bitget
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):